Cargando…

Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation.

To study the evolution of camptothecin (CPT) resistance, we have established two small-cell lung cancer cell lines with low (3.2-fold, NYH/CAM15) and high (18-fold, NYH/CAM50) resistance to CPT by stepwise drug exposure. NYH/CAM50 cells had reduced topoisomerase I (topo I) content and activity, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sorensen, M., Sehested, M., Christensen, I. J., Larsen, J. K., Jensen, P. B.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1998
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150415/ https://www.ncbi.nlm.nih.gov/pubmed/9649127

Ejemplares similares

Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
por: Sorensen, M., et al.
Publicado: (1995)

Evodiamine Stabilizes Topoisomerase I-DNA Cleavable Complex to Inhibit Topoisomerase I Activity
por: Chan, Agnes L.-F., et al.
Publicado: (2009)

Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors.
por: Davies, S. L., et al.
Publicado: (1997)

New Topoisomerase I mutations are associated with resistance to camptothecin
por: Gongora, Céline, et al.
Publicado: (2011)

Characterization of DNA Topoisomerase-1 in Spodoptera exigua for Toxicity Evaluation of Camptothecin and Hydoxy-Camptothecin
por: Zhang, Lan, et al.
Publicado: (2013)

Differential induction of Leishmania donovani bi-subunit topoisomerase I–DNA cleavage complex by selected flavones and camptothecin: activity of flavones against camptothecin-resistant topoisomerase I
por: Das, Benu Brata, et al.
Publicado: (2006)

Targeting of Topoisomerase I for Prognoses and Therapeutics of Camptothecin-Resistant Ovarian Cancer
por: Lee, Yu-Chieh, et al.
Publicado: (2015)

Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study
por: Tesauro, Cinzia, et al.
Publicado: (2019)

Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway
por: Ando, Koji, et al.
Publicado: (2017)

Novel clinical indenoisoquinoline topoisomerase I inhibitors: a twist around the camptothecins
por: Pommier, Yves, et al.
Publicado: (2018)

Mechanism of action of non-camptothecin inhibitor Genz-644282 in topoisomerase I inhibition
por: Nishida, Masahiro, et al.
Publicado: (2022)

Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer.
por: Kreisholt, J., et al.
Publicado: (1998)

Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity
Publicado: (1996)

Three missense mutations of DNA topoisomerase I in highly camptothecin-resistant colon cancer cell sublines
por: ARAKAWA, YASUHIRO, et al.
Publicado: (2013)

Menogaril, an Anthracycline Derivative, Inhibits DNA Topoisomerase II by Stabilizing Cleavable Complexes
por: Ono, Katsuhiro, et al.
Publicado: (1992)

Evaluation of Two Models for Human Topoisomerase I Interaction with dsDNA and Camptothecin Derivatives
por: Laco, Gary S.
Publicado: (2011)

The benzylisoquinoline alkaloids, berberine and coptisine, act against camptothecin-resistant topoisomerase I mutants
por: Inoue, Naomi, et al.
Publicado: (2021)

Decreased Camptothecin Sensitivity of the Stem-Cell-Like Fraction of Caco2 Cells Correlates with an Altered Phosphorylation Pattern of Topoisomerase I
por: Roy, Amit, et al.
Publicado: (2014)

Sensitization of Cancer Cells to Radiation and Topoisomerase I Inhibitor Camptothecin Using Inhibitors of PARP and Other Signaling Molecules
por: Matsuno, Yusuke, et al.
Publicado: (2018)

In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
por: Jensen, P. B., et al.
Publicado: (1997)

Effects of camptothecin derivatives and topoisomerase dual inhibitors on Trypanosoma cruzi growth and ultrastructure
por: Lacombe, Otto Kischlat, et al.
Publicado: (2014)

Nitric Oxide Down-Regulates Topoisomerase I and Induces Camptothecin Resistance in Human Breast MCF-7 Tumor Cells
por: Sharma, Nilesh K., et al.
Publicado: (2015)

CK2-Mediated Hyperphosphorylation of Topoisomerase I Targets Serine 506, Enhances Topoisomerase I–DNA Binding, and Increases Cellular Camptothecin Sensitivity
por: Bandyopadhyay, Keya, et al.
Publicado: (2012)

Tryptophane-205 of human topoisomerase I is essential for camptothecin inhibition of negative but not positive supercoil removal
por: Frøhlich, Rikke From, et al.
Publicado: (2007)

Poly(ADP-ribose) polymers regulate DNA topoisomerase I (Top1) nuclear dynamics and camptothecin sensitivity in living cells
por: Das, Subhendu K., et al.
Publicado: (2016)

Different Camptothecin Sensitivities in Subpopulations of Colon Cancer Cells Correlate with Expression of Different Phospho-Isoforms of Topoisomerase I with Different Activities
por: Tesauro, Cinzia, et al.
Publicado: (2020)

Replacement of the Human Topoisomerase Linker Domain with the Plasmodial Counterpart Renders the Enzyme Camptothecin Resistant
por: Arnò, Barbara, et al.
Publicado: (2013)

Camptothecin exhibits topoisomerase1-independent KMT1A suppression and myogenic differentiation in alveolar rhabdomyosarcoma cells
por: Wolff, David W., et al.
Publicado: (2018)

Determination of the Effects of Camptothecin on Cell Cycling and Apoptosis in Human Leukaemic Cell Lines
por: Cox, Anne, et al.
Publicado: (2001)

The inhibitory effects of camptothecin, a topoisomerase I inhibitor, on collagen synthesis in fibroblasts from patients with systemic sclerosis
por: Czuwara-Ladykowska, Joanna, et al.
Publicado: (2001)

Antisense transcripts enhanced by camptothecin at divergent CpG-island promoters associated with bursts of topoisomerase I-DNA cleavage complex and R-loop formation
por: Marinello, Jessica, et al.
Publicado: (2013)

The different cleavage DNA sequence specificity explains the camptothecin resistance of the human topoisomerase I Glu418Lys mutant
por: Fiorani, Paola, et al.
Publicado: (2006)

PARP-1-dependent RND1 transcription induced by topoisomerase I cleavage complexes confers cellular resistance to camptothecin
por: Mouly, Laetitia, et al.
Publicado: (2018)

Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.
por: Jensen, P. B., et al.
Publicado: (1993)

Molecular mechanism of the camptothecin resistance of Glu710Gly topoisomerase IB mutant analyzed in vitro and in silico
por: Tesauro, Cinzia, et al.
Publicado: (2013)

Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants
por: Pavillard, V, et al.
Publicado: (2001)

Semi‐quantitative Analysis of DNA Topoisomerase‐I mRNA Level Using Reverse Transcription‐Polymerase Chain Reaction in Cancer Cell Lines: Its Relation to Cytotoxicity against Camptothecin Derivative
por: Niwa, Kenji, et al.
Publicado: (1994)

Mutations of human DNA topoisomerase I at poly(ADP-ribose) binding sites: modulation of camptothecin activity by ADP-ribose polymers
por: Tesauro, Cinzia, et al.
Publicado: (2014)

Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells
por: Jensen, Lars H, et al.
Publicado: (2004)

Bromomaleimide-Linked Bioconjugates Are Cleavable in Mammalian Cells
por: Moody, Paul, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_1j4t7pjpe0cj950ies04ld8vll